Literature DB >> 3815271

Heterogeneity of DNA ploidy in patients with undifferentiated carcinomas of the stomach.

M Haraguchi, T Okamura, D Korenaga, S Tsujitani, P Marin, K Sugimachi.   

Abstract

DNA ploidy was determined by cytophotometric DNA analysis in 20 patients with undifferentiated carcinomas of the stomach with serosal invasion. Measurements of DNA content were performed in 100 cells each in intramucosal, submucosal, muscular, and subserosal parts of a tumor. According to dispersion on the DNA histogram, DNA ploidy patterns were divided into low and high ploidy groups. Fourteen tumors (70%) showed the same ploidy in every layer (homogeneous DNA ploidy), 13 (65%) were low ploidy and, 1 (5%) was high ploidy. Heterogeneity of DNA ploidy was observed in the remaining six tumors (30%), which showed low ploidy in the mucosa, but high ploidy was observed in one or two deeper layers. In the six with heterogeneous DNA ploidy, there was more frequent metastasis to the lymph nodes (100%) and to the peritoneum (67%) than those with homogeneous DNA ploidy (50% and 21%, respectively). Cytophotometric DNA analysis of cells of undifferentiated gastric tumors suggested that there may be behavioral changes, depending on the degree of penetration into the gastric wall.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815271     DOI: 10.1002/1097-0142(19870301)59:5<922::aid-cncr2820590511>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  [Comparison of DNA analysis with histomorphologic parameters in stomach cancer].

Authors:  T Böttger; H Gabbert; M Stöckle; S Wellek; H Menke; H C Jauckus; A Grenz; A Heintz; T Junginger
Journal:  Langenbecks Arch Chir       Date:  1992

Review 2.  Prognostic factors for gastric cancer influencing clinical practice.

Authors:  J D Harrison; J W Fielding
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

3.  Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.

Authors:  Thorsten O Götze; Pompiliu Piso; Sylvie Lorenzen; Ulli S Bankstahl; Claudia Pauligk; Moustafa Elshafei; Giuseppe Amato; Daniel Reim; Wolf O Bechstein; Alfred Königsrainer; Stefan P Mönig; Beate Rau; Matthias Schwarzbach; Salah-Eddin Al-Batran
Journal:  BMC Cancer       Date:  2021-10-29       Impact factor: 4.430

4.  DNA ploidy in early gastric cancer and its relationship to prognosis.

Authors:  X de Aretxabala; Y Yonemura; K Sugiyama; T Kamata; K Konishi; K Miwa; I Miyazaki
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.